Genomic correlates of response to CTLA-4 blockade in metastatic melanoma; Improved survival with MEK inhibition in BRAF-mutated melanoma; Induced pluripotent stem cells generated without viral integration; Directly reprogrammed fibroblasts show global epigenetic remodeling and widespread tissue contribution; Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer; Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma; Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial; Immortalization eliminates a roadblock during cellular reprogramming into iPS cells; A high-efficiency system for the generation and study of human induced pluripotent stem cells; Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study; Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy; Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy; Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma; Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression; Reprogramming of neural progenitor cells into induced pluripotent stem cells in the absence of exogenous Sox2 expression; An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma; Myeloid-derived suppressor cells hinder the anti-cancer activity of immune checkpoint inhibitors; Targeting myeloid-derived suppressor cells to bypass tumor-induced immunosuppression; Sox2 is dispensable for the reprogramming of melanocytes and melanoma cells into induced pluripotent stem cells; Deep learning outperformed 136 of 157 dermatologists in a head-to-head dermoscopic melanoma image classification task
